Guideline Updates G26: Everything Is Connected: The 2026 CKM Syndrome Guideline

The first unified AHA/ACC/ADA/ASN guideline defines cardiovascular-kidney-metabolic syndrome, introduces a 0 to 4 staging system, mandates PREVENT-based risk estimation, and places SGLT2 inhibitors and GLP-1 therapies at the center of cardiometabolic care